The mechanisms by which liraglutide inhibit PAH may be due to activation of eNOS and sGC in PA endothelium, and inhibition of ROCK II in PASMCs by liraglutide may protect against MCT-induced chronic PAH over long-term administration. This evidence concerns the gene NOS3 and pulmonary arterial hypertension.